Skip to main content
. 2023 Jul 17;131(7):077006. doi: 10.1289/EHP12259

Figure 1.

Figure 1, Part 1, is a scientific illustration titled Baseline of nicotinamide mononucleotide-treated mice without being exposed to filtered air or particulate matter that displays the following information: At week 0, nicotinamide mononucleotide treatment begins. Nicotinamide mononucleotide supplementation is done for 18 weeks, including nicotinamide mononucleotide freshly prepared in drinking water every 3 days; water consumption, and food intake monitoring every 3 days; and weekly body weight measurements. After 18 weeks, the following things were monitored: fasted glucose level, intraperitoneal glucose tolerance testing, insulin tolerance testing, hepatic triglyceride level; NAD plus and ATP content in multiple tissues; and liver transcriptomic sequencing. Figure 1, Part 2, is a scientific illustration titled Effects of oral nicotinamide mononucleotide supplementation on particulate matter-induced chronic lung injury in mice and displays the following information: Two weeks before the exposure, nicotinamide mononucleotide treatment was begun. For the next 18 weeks after nicotinamide mononucleotide treatment, nicotinamide mononucleotide supplementation was done, including freshly prepared nicotinamide mononucleotide in drinking water every 3 days and weekly body weight measurements. On week 0, particulate matter exposure was begun. The daily particulate matter begin subscript 2.5 end subscript concentration was monitored for the next 16 weeks. After 16 weeks of particulate matter exposure, the following things were monitored: histopathology; single-cell R N A transcriptomic sequencing of whole lung cells; and plasma, bronchoalveolar lavage fluid, and tissue collection.

A schematic diagram illustrates the experimental design in this study. The experiment was conducted in two parts: Part I, Characterization of metabolic alterations in mice receiving 18-wk NMN supplementation; and Part II, Effects of NMN supplementation on PM exposure-induced chronic lung injury (NMN supplementation started 2 wk prior to 16-wk PM exposure). Note: ATP, adenosine triphosphate; BALF, bronchoalveolar lavage fluid; IPGTT, intraperitoneal glucose tolerance testing; ITT, insulin tolerance testing; NAD+, nicotinamide adenine dinucleotide; NMN, nicotinamide mononucleotide; PM, particulate matter; scRNA-seq, single-cell RNA transcriptomic sequencing; TG, triglyceride.